Sun Pharmaceutical Industries Moat Analysis: Score & Risks
Sun Pharmaceutical Industries Ltd.
A first-pass moat teardown of Sun Pharmaceutical Industries Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.
Sun Pharmaceutical Industries Ltd. scores 5.41 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“In Specialty business, we have built commercial infrastructure in certain large pharma markets and we believe this makes Sun a partner of choice for innovation-led companies”
“Not dependent on imported technology, can make high-end products available at competitive prices by using indigenously developed manufacturing processes and formulation technologies.”
“Gross margin was favorable aided by lower material cost due to better product mix and a higher share of sales from the Innovative Medicines.”
“Sun Pharma discontinued clinical trials of SCD-044 and has no further plans for development of SCD-044”
“certain one-time sales to our partner and that has given Q3 FY25 high base and that is one reason for the growth looking lower in H1”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion